In this post I will highlight some of the AACR Late-breaker abstracts that I am watching for, mostly related to clinical trial results. The big trials tend to be saved for ASCO in June, but there should be some interesting data nonetheless.
Full coverage:
Introduction
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Preview Part 4 (ASTX, ARQL, BPAX)
Full coverage:
Introduction
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Preview Part 4 (ASTX, ARQL, BPAX)
Abstract numbers link you to fulltext c/o AACR.
A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors (LB-289) Tekmira Pharma $TKMR
Cabozantinib (cabo) + abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study (LB-166) Exelixis EXEL
Phase I dose escalation study of abexinostat and doxorubicin in patients with metastatic sarcomas (LB-167) Pharmacyclics PCYC
A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC) (LB-159) Immunomedics IMMU
Randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Preliminary results of the feasibility of the SHIVA trial (LB-171) General interest
LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer (LB-122) Eli Lilly $LLY plus much recent buzz for competing CDK4/6 compounds from Pfizer PFE (PD-0332991 aka palbciclib) and Astex Pharma ASTX / Novartis NVS (LEE011)
Comprehensive preclinical evaluation of VE-822, the first ATR-targeted drug candidate: a novel approach to transforming the efficacy of DNA damaging agents (LB-299) Vertex Pharma VRTX
A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors (LB-289) Tekmira Pharma $TKMR
Cabozantinib (cabo) + abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study (LB-166) Exelixis EXEL
Phase I dose escalation study of abexinostat and doxorubicin in patients with metastatic sarcomas (LB-167) Pharmacyclics PCYC
A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC) (LB-159) Immunomedics IMMU
Randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Preliminary results of the feasibility of the SHIVA trial (LB-171) General interest
LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer (LB-122) Eli Lilly $LLY plus much recent buzz for competing CDK4/6 compounds from Pfizer PFE (PD-0332991 aka palbciclib) and Astex Pharma ASTX / Novartis NVS (LEE011)
Comprehensive preclinical evaluation of VE-822, the first ATR-targeted drug candidate: a novel approach to transforming the efficacy of DNA damaging agents (LB-299) Vertex Pharma VRTX
RSS Feed
